Publications

  • San Miguel, J. F., B. Paiva, and J. J. Lasarte. 2015. Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells. Cancer Cell 28:281-283.

  • Melero, I., and J. J. Lasarte. 2015. Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med 372:783.

  • Matsoukas, M., A. Aranguren-Ibáñez, T. Lozano, V. Nunes, J. Lasarte, L. Pardo, and M. Pérez-Riba. 2015. Identification of non-peptidic inhibitors of Calcineurin-NFATc signaling that mimic the PxIxIT motif of Calcineurin interactors. Science Signaling In press.

  • Lozano, T., L. Villanueva, M. Durantez, M. Gorraiz, M. Ruiz, V. Belsue, J. I. Riezu-Boj, S. Hervas-Stubbs, J. Oyarzabal, H. Bandukwala, A. R. Lourenco, P. J. Coffer, P. Sarobe, J. Prieto, N. Casares, and J. J. Lasarte. 2015. Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation. J Immunol 195:3180-3189.

  • Lozano, T., N. Casares, and J. J. Lasarte. 2013. Searching for the Achilles Heel of FOXP3. Front Oncol 3:294.

  • Riezu-Boj, J. I., E. Larrea, R. Aldabe, L. Guembe, N. Casares, E. Galeano, I. Echeverria, P. Sarobe, I. Herrero, B. Sangro, J. Prieto, and J. J. Lasarte. 2011. Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. J Hepatol 54:422-431.

  • Ma, Y., L. Aymeric, C. Locher, S. R. Mattarollo, N. F. Delahaye, P. Pereira, L. Boucontet, L. Apetoh, F. Ghiringhelli, N. Casares, J. J. Lasarte, G. Matsuzaki, K. Ikuta, B. Ryffel, K. Benlagha, A. Tesniere, N. Ibrahim, J. Dechanet-Merville, N. Chaput, M. J. Smyth, G. Kroemer, and L. Zitvogel. 2011. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 208:491-503.

  • Arribillaga, L., J. Dotor, M. Basagoiti, J. I. Riezu-Boj, F. Borras-Cuesta, J. J. Lasarte, P. Sarobe, M. E. Cornet, and E. Feijoo. 2011. Therapeutic effect of a peptide inhibitor of TGF-beta on pulmonary fibrosis. Cytokine 53:327-333.

  • Casares, N., F. Rudilla, L. Arribillaga, D. Llopiz, J. I. Riezu-Boj, T. Lozano, J. Lopez-Sagaseta, L. Guembe, P. Sarobe, J. Prieto, F. Borras-Cuesta, and J. J. Lasarte. 2010. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J Immunol 185:5150-5159.

  • Hermida, N., B. Lopez, A. Gonzalez, J. Dotor, J. J. Lasarte, P. Sarobe, F. Borras-Cuesta, and J. Diez. 2009. A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res 81:601-609.

  • Gil-Guerrero, L., J. Dotor, I. L. Huibregtse, N. Casares, A. B. Lopez-Vazquez, F. Rudilla, J. I. Riezu-Boj, J. Lopez-Sagaseta, J. Hermida, S. Van Deventer, J. Bezunartea, D. Llopiz, P. Sarobe, J. Prieto, F. Borras-Cuesta, and J. J. Lasarte. 2008. In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta1. J Immunol 181:126-135.

  • Larrea, E., J. I. Riezu-Boj, L. Gil-Guerrero, N. Casares, R. Aldabe, P. Sarobe, M. P. Civeira, J. L. Heeney, C. Rollier, B. Verstrepen, T. Wakita, F. Borras-Cuesta, J. J. Lasarte, and J. Prieto. 2007. Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol 81:3662-3666.

  • Dotor, J., A. B. Lopez-Vazquez, J. J. Lasarte, P. Sarobe, M. Garcia-Granero, J. I. Riezu-Boj, A. Martinez, E. Feijoo, J. Lopez-Sagaseta, J. Hermida, J. Prieto, and F. Borras-Cuesta. 2007. Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library. Cytokine 39:106-115.

  • Ezquerro, I. J., J. J. Lasarte, J. Dotor, I. Castilla-Cortazar, M. Bustos, I. Penuelas, G. Blanco, C. Rodriguez, C. Lechuga Mdel, P. Greenwel, M. Rojkind, J. Prieto, and F. Borras-Cuesta. 2003. A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine 22:12-20.

  • Casares, N., L. Arribillaga, P. Sarobe, J. Dotor, A. Lopez-Diaz de Cerio, I. Melero, J. Prieto, F. Borras-Cuesta, and J. J. Lasarte. 2003. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 171:5931-5939.



"We are involved in the translational development of new therapeutic tools for the treatment of different types of cancers and infectious diseases". Dr. Juan José Lasarte.

More information:

Contact

Contact:
Cristina López
Avda. Pío XII, 53
31008 Pamplona
Spain

(+34) 948 194 700 Ext. 6021
clopezg@unav.es